ImmunoPrecise Financial Statements From 2010 to 2025

Stocks . USA . 
Stock . ImmunoPrecise Antibodies
HYFT Stock   1.65  0.05  2.94%   
Analyzing historical trends in various income statement and balance sheet accounts from ImmunoPrecise Antibodies' financial statements helps investors evaluate the company's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting ImmunoPrecise Antibodies' valuation are summarized below:
Gross Profit
14.1 M
Profit Margin
(1.16)
Market Capitalization
81.7 M
Enterprise Value Revenue
3.3574
Revenue
25.2 M
There are currently one hundred twenty fundamental trends for ImmunoPrecise Antibodies that can be evaluated and compared over time across competitors. All traders should confirm ImmunoPrecise Antibodies' regular fundamentals against the performance from 2010 to 2025 and make sure the trends continue to evolve in the right direction. Market Cap is likely to drop to about 2.8 M in 2025. Enterprise Value is likely to drop to about 2.9 M in 2025

ImmunoPrecise Antibodies Total Revenue

25.53 Million

Check ImmunoPrecise Antibodies financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among ImmunoPrecise Antibodies' main balance sheet or income statement drivers, such as Depreciation And Amortization of 5.3 M, Total Revenue of 25.5 M or Gross Profit of 12.1 M, as well as many indicators such as Price To Sales Ratio of 3.2 K, Dividend Yield of 0.0863 or Days Sales Outstanding of 3.5 K. ImmunoPrecise financial statements analysis is a perfect complement when working with ImmunoPrecise Antibodies Valuation or Volatility modules.
  
Build AI portfolio with ImmunoPrecise Stock
Check out the analysis of ImmunoPrecise Antibodies Correlation against competitors.
For more information on how to buy ImmunoPrecise Stock please use our How to Invest in ImmunoPrecise Antibodies guide.

ImmunoPrecise Antibodies Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets46.7 M44.4 M29.9 M
Slightly volatile
Total Current Liabilities9.5 M9 M4.4 M
Slightly volatile
Property Plant And Equipment Net17.1 M16.3 M4.8 M
Slightly volatile
Accounts Payable5.5 M5.3 M1.8 M
Slightly volatile
Cash11.2 M10.7 M7.4 M
Slightly volatile
Non Current Assets Total27 M25.7 M18.5 M
Slightly volatile
Cash And Short Term Investments11.2 M10.7 M7.6 M
Slightly volatile
Net Receivables5 M4.8 M2.1 M
Slightly volatile
Common Stock Shares Outstanding35.1 M33.4 M12.4 M
Slightly volatile
Short Term Investments88.9293.6164.5 K
Slightly volatile
Liabilities And Stockholders Equity46.7 M44.4 M29.9 M
Slightly volatile
Other Current Assets1.2 M1.2 M829.8 K
Slightly volatile
Other Stockholder Equity9.4 M12.8 M9.8 M
Pretty Stable
Total Liabilities21.9 M20.8 M9.6 M
Slightly volatile
Total Current Assets19.7 M18.8 M11.4 M
Slightly volatile
Non Current Liabilities Total7.2 M11.8 M5.4 M
Slightly volatile
Short and Long Term Debt Total14.1 M13.4 M4.6 M
Slightly volatile
Short Term Debt3.3 M3.2 M1.4 M
Slightly volatile
Inventory1.3 M2.1 M862.8 K
Slightly volatile
Intangible Assets1 M1.1 M7.7 M
Slightly volatile
Common Stock143.2 M136.4 M50.4 M
Slightly volatile
Good Will11.5 M8.2 M8.1 M
Slightly volatile
Capital Lease Obligations9.8 M13.4 M3.9 M
Slightly volatile
Net Invested Capital38.7 M23.6 M67.2 M
Slightly volatile
Property Plant And Equipment Gross19.8 M24 M12.3 M
Slightly volatile
Short and Long Term Debt1 M1.2 M1.3 M
Slightly volatile
Capital Stock134.2 M136.4 M117.7 M
Slightly volatile
Net Working Capital10.4 M9.7 M23.3 M
Slightly volatile

ImmunoPrecise Antibodies Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization5.3 M5.1 M2.3 M
Slightly volatile
Total Revenue25.5 M24.3 M11 M
Slightly volatile
Other Operating Expenses38.4 M36.6 M17.2 M
Slightly volatile
Total Operating Expenses25 M23.8 M9.7 M
Slightly volatile
Interest Expense9.4 K9.9 K153.3 K
Pretty Stable
Cost Of Revenue13.4 M12.8 M6.9 M
Slightly volatile
Selling General Administrative15.5 M14.7 M7.1 M
Slightly volatile
Selling And Marketing Expenses4.5 M4.3 M1.3 M
Slightly volatile
Research Development3.4 M4.9 M2.5 M
Slightly volatile
Interest Income19.7 K20.7 K220.8 K
Slightly volatile
Reconciled Depreciation5.9 M5.1 M4.3 M
Slightly volatile

ImmunoPrecise Antibodies Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash Flow4 M3.5 M6.4 M
Slightly volatile
Depreciation5.4 M5.1 M2.3 M
Slightly volatile
End Period Cash Flow11.3 M10.8 M7.5 M
Slightly volatile
Stock Based Compensation422.8 K445 K909.6 K
Slightly volatile
Dividends Paid94.7 K81 K122.5 K
Slightly volatile
Issuance Of Capital Stock12.8 M12.2 M4.6 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio3.2 K0.8299208
Slightly volatile
Dividend Yield0.08630.08220.0484
Slightly volatile
Days Sales Outstanding3.5 K72.1601285
Slightly volatile
Average Payables245.1 K130.6 K329.5 K
Slightly volatile
Stock Based Compensation To Revenue0.01740.01830.0863
Very volatile
Capex To Depreciation19.530.15613.4078
Pretty Stable
EV To Sales3.2 K0.9426203
Slightly volatile
Inventory Turnover0.556.11426.8418
Pretty Stable
Days Of Inventory On Hand66559.6974530
Slightly volatile
Payables Turnover0.00582.42462.8266
Slightly volatile
Sales General And Administrative To Revenue0.750.60610.6982
Pretty Stable
Average Inventory5.8 K6.1 K277.1 K
Pretty Stable
Research And Ddevelopement To Revenue0.170.20160.2223
Very volatile
Capex To Revenue23.020.03291.5527
Slightly volatile
Cash Per Share0.07290.31950.4628
Pretty Stable
Days Payables Outstanding63.3 K15122 K
Slightly volatile
Intangibles To Total Assets0.02850.20920.3701
Very volatile
Current Ratio0.172.0812.0932
Pretty Stable
Receivables Turnover0.115.05825.0151
Slightly volatile
Capex Per Share0.03690.02390.0416
Slightly volatile
Average Receivables1.3 K1.4 K830.5 K
Pretty Stable
Revenue Per Share0.00220.72820.7512
Very volatile
Interest Debt Per Share0.140.40180.2057
Slightly volatile
Debt To Assets1.60.30160.4263
Very volatile
Operating Cycle665132574
Slightly volatile
Days Of Payables Outstanding63.3 K15122 K
Slightly volatile
Long Term Debt To Capitalization0.02860.03010.1226
Slightly volatile
Quick Ratio0.171.84851.9811
Pretty Stable
Net Income Per E B T0.720.88230.9984
Pretty Stable
Cash Ratio0.01511.18341.2365
Pretty Stable
Days Of Inventory Outstanding66559.6974530
Slightly volatile
Days Of Sales Outstanding3.5 K72.1601285
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.561.12461.3361
Slightly volatile
Fixed Asset Turnover6.0E-41.49473.6975
Slightly volatile
Debt Ratio1.60.30160.4263
Very volatile
Price Sales Ratio3.2 K0.8299208
Slightly volatile
Asset Turnover4.0E-40.5470.4823
Slightly volatile

ImmunoPrecise Antibodies Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap2.8 M20.2 M43.4 M
Slightly volatile
Enterprise Value2.9 M22.9 M40 M
Slightly volatile

ImmunoPrecise Fundamental Market Drivers

About ImmunoPrecise Antibodies Financial Statements

ImmunoPrecise Antibodies shareholders use historical fundamental indicators, such as revenue or net income, to determine how well the company is positioned to perform in the future. Although ImmunoPrecise Antibodies investors may analyze each financial statement separately, they are all interrelated. The changes in ImmunoPrecise Antibodies' assets and liabilities, for example, are also reflected in the revenues and expenses on on ImmunoPrecise Antibodies' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue1.3 M1.3 M
Total Revenue24.3 M25.5 M
Cost Of Revenue12.8 M13.4 M
Stock Based Compensation To Revenue 0.02  0.02 
Sales General And Administrative To Revenue 0.61  0.75 
Research And Ddevelopement To Revenue 0.20  0.17 
Capex To Revenue 0.03  23.02 
Ebit Per Revenue(0.50)(603.21)

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for ImmunoPrecise Stock Analysis

When running ImmunoPrecise Antibodies' price analysis, check to measure ImmunoPrecise Antibodies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ImmunoPrecise Antibodies is operating at the current time. Most of ImmunoPrecise Antibodies' value examination focuses on studying past and present price action to predict the probability of ImmunoPrecise Antibodies' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ImmunoPrecise Antibodies' price. Additionally, you may evaluate how the addition of ImmunoPrecise Antibodies to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2025 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY